RxDoctor Payments Data

David Sidebottom, MD

Infectious Disease · Lowell, MANPI 1174580898

Payments from drug & device makers

$32,172in general payments, 2019–2025

Across 559 payments — averaging $57.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$11K
  • Insmed, Inc.$9K
  • Gilead$5K
  • Viiv Healthcare Company$2K
  • Merck$958
  • Cepheid$920
  • plus $3K from 18 others

What the payments were for

  • Consulting fees$7732%
  • Speaking & faculty fees$15,36748%
  • Travel & lodging$1,4354%
  • Food & beverage$14,02944%
  • Education$5682%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,172 in reported general payments places this provider in the 80th percentile of 368 infectious disease providers in Massachusetts.

See all infectious disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$75,927
Medicare patients
282
Services billed
532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala66$282,845
GenvoyaElviteg/Cob/Emtri/Tenof Alafen37$167,660
JulucaDolutegravir/Rilpivirine19$70,501
StribildElviteg/Cob/Emtri/Tenofo Disop15$67,837
CresembaIsavuconazonium Sulfate16$56,196
TriumeqAbacavir/Dolutegravir/Lamivudi14$51,998
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$50,457
DescovyEmtricitabine/Tenofov Alafenam16$39,558
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df60$33,502
TivicayDolutegravir Sodium12$30,625
Isentress HdRaltegravir Potassium12$23,008
Entecavir39$18,446
Maraviroc12$13,603
ErtapenemErtapenem Sodium17$5,061
Cephalexin38$3,973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Stribild, Descovy$5,186$557,900134 claims
Viiv Healthcare CompanyJuluca, Triumeq, Tivicay$2,077$153,12545 claims
Astellas Pharma US IncCresemba$195$56,19616 claims
MerckIsentress Hd$958$23,00812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 368 infectious disease providers in Massachusetts.

Other infectious disease in Lowell

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →